Catapres Shortage: What Providers and Prescribers Need to Know in 2026

Catapres Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty finding Catapres, this provider briefing covers the current state of Clonidine availability, the history behind the brand discontinuation, prescribing implications, and tools to help your patients access their medication.

Provider Briefing: Brand Catapres Is Permanently Discontinued

Brand-name Catapres (Clonidine Hydrochloride tablets, manufactured by Boehringer Ingelheim) was permanently discontinued in 2022. This followed a voluntary recall of certain lots in October 2021 due to stability testing concerns. Boehringer Ingelheim subsequently decided not to resume production.

Key point for prescribers: Prescriptions written for "Catapres" may create confusion at the pharmacy level. Update all active prescriptions and templates to generic Clonidine Hydrochloride to ensure seamless dispensing.

Timeline of Events

• October 2021: Boehringer Ingelheim issues voluntary recall of specific Catapres tablet lots due to stability testing findings
• Q1 2022: Company confirms supply disruptions are ongoing; patients advised to consult providers
• April 2022: Boehringer Ingelheim officially discontinues Catapres tablets, citing the availability of generic alternatives
• 2022-2025: Generic Clonidine tablet supply remains stable. Intermittent transdermal patch shortages reported.
• 2026: Generic Clonidine IR tablets widely available. Patch supply improved but still subject to occasional disruptions.

Prescribing Implications

Updating Prescriptions

The most immediate action item is ensuring your EMR templates and active prescriptions specify Clonidine Hydrochloride rather than Catapres. This prevents:

• Pharmacy dispensing delays
• Patient confusion when they can't find "Catapres"
• Insurance claim complications (the brand NDC is no longer active)

Formulation Considerations

When prescribing Clonidine, consider the full range of available formulations based on patient needs:

• IR tablets (0.1 mg, 0.2 mg, 0.3 mg): Most widely available and affordable. Dosed twice daily. Best for most hypertension patients. Cost: $4-$25/month cash; $3-$5 with discount cards.
• Transdermal patch (0.1, 0.2, 0.3 mg/day): Applied weekly. Ideal for patients with adherence challenges or GI concerns. Supply can be intermittent. Cost: $28-$124/month cash; $28-$45 with coupons.
• ER tablets (Kapvay, Onyda XR): Extended-release options. Kapvay is FDA-approved for ADHD in pediatric patients (6-17). Onyda XR is a newer suspension for hypertension. Cost: $18-$170/month; significantly less with coupons.
• Epidural injection (Duraclon): For severe cancer pain management. Specialist use only.

Rebound Hypertension Advisory

When transitioning patients between formulations or to alternative medications, remember that abrupt Clonidine discontinuation poses a real clinical risk. Rebound hypertension can occur within 18-72 hours of sudden cessation, presenting with:

• Rapid blood pressure elevation
• Tachycardia, agitation, tremor
• Headache, diaphoresis
• Rare but reported: hypertensive encephalopathy, stroke, cardiac events

Always taper Clonidine gradually over 2-4 days when discontinuing. If a patient is on concurrent beta-blocker therapy, discontinue the beta-blocker first (several days before beginning Clonidine taper) to reduce rebound risk.

Current Availability Picture

What's Available

• Generic Clonidine IR tablets: Widely available from multiple manufacturers. No FDA shortage listed.
• Generic Clonidine transdermal patches: Available but subject to intermittent supply disruptions.
• Clonidine ER tablets: Available through most pharmacies, though less commonly stocked than IR formulations.

What's Not Available

• Brand Catapres tablets: Permanently discontinued.
• Brand Catapres-TTS patches: Brand discontinued; generic patches remain available.

Cost and Access Considerations

Generic Clonidine is one of the most affordable antihypertensive medications available:

• Most insurance plans cover generic Clonidine as a Tier 1 (preferred generic) medication with copays of $0-$10.
• Cash price for IR tablets is approximately $22 for a 30-day supply without coupons.
• Discount card price can be as low as $3-$5 (GoodRx, SingleCare).
• Prior authorization is generally not required for IR tablets. ER formulations and patches may require PA or step therapy with some payers.

For patients struggling with cost, savings programs and coupons can help. The Boehringer Ingelheim Cares Foundation Patient Assistance Program may cover eligible patients who need other BI medications, though generic Clonidine's low cost makes PAPs rarely necessary.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder helps patients locate pharmacies with Clonidine in stock. Consider directing patients to medfinder.com/providers as a resource when they report difficulty finding their medication. It shows real-time pharmacy availability by location.

Patient Education Resources

Direct patients to these evidence-based resources:

• What Is Catapres: Uses, Dosage, and What You Need to Know
• Catapres Side Effects: What to Expect and When to Call Your Doctor
• Catapres Drug Interactions: What to Avoid

Therapeutic Alternatives Reference

When Clonidine is unavailable or contraindicated:

• Guanfacine (Tenex IR, Intuniv ER): Same drug class. Longer half-life allows once-daily dosing. May cause less sedation. FDA-approved for ADHD (Intuniv).
• Methyldopa: Centrally acting antihypertensive. Preferred in pregnancy-related hypertension.
• HCTZ or Amlodipine: For patients who need hypertension management only and can transition to a different drug class.

See the patient-facing version: Alternatives to Catapres If You Can't Fill Your Prescription.

Looking Ahead

The Clonidine market is mature and well-supplied at the generic level. We do not anticipate widespread shortage risks for IR tablets. However, providers should:

• Monitor transdermal patch availability — this remains the most supply-vulnerable formulation
• Educate patients that Catapres is gone but Clonidine isn't — many patients don't realize they're the same drug
• Consider 90-day prescriptions for stable patients to reduce refill-related access gaps
• Document formulation flexibility in care plans so pharmacists can substitute when needed

Final Thoughts

The Catapres brand discontinuation was an orderly transition with no patient safety implications, given the robust generic Clonidine supply. The primary action items for providers are straightforward: update prescriptions to generic Clonidine, counsel patients on the brand change, and use tools like Medfinder to help patients locate pharmacies with stock.

For a patient-facing version of this update, see Catapres Shortage Update: What Patients Need to Know in 2026. For guidance on helping patients find medication and manage costs, see How to Help Your Patients Find Catapres in Stock: A Provider's Guide.